BCBS Florida Medical Policy Updates – December 2018

Click here to view the Florida Blue Cross Blue Shield Medical Policy Updates »

December 2018 Medical Policy Updates:

• Abiraterone Acetate (Yonsa , Zytiga ) Tablet
• Adalimumab (Humira ) Injection
• Agalsidase Beta (Fabrazyme ) IV
• Alemtuzumab (Lemtrada™) IV
• Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in
• Avatrombopag (Doptelet)
• Bariatric Surgery
• Cabozantinib capsules and tablets
• Cenegermin-bkbj (Oxervate ) Ophthalmic
• Clotting Factors and Coagulant Blood Products
• Cobimetinib (Cotellic ) Tablet
• Computed Tomography (CT) Abdomen and Pelvis
• Dabrafenib (Tafinlar®) Capsules
• Dacomitinib (Vizimpro®)
• Denosumab (Prolia™; Xgeva™) Injection
• Dimethyl Fumarate (Tecfidera®) Capsule
• Dopamine Transporter Imaging with Single-Photon Emission Computed Tomography
• Drugs and Biologics without a Medical Coverage Guideline (Orphan Drugs and Off-Label and Labeled Use of FDA Approved Drugs)
• Dupilumab (Dupixent ) Injection
• Duvelisib (Copiktra ) Capsule
• Fingolimod (Gilenya™) Capsule
• Genetic Testing
• Granulocyte Colony Stimulating Factors
• Hereditary Angioedema Drug Therapy
• Immune Globulin Therapy
• Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
• Inotersen (Tegsedi™)
• Investigational Services
• Ipilimumab (Yervoy™) Injection
• Ivosidenib (Tibsovo ) Tablet
• Ixazomib (Ninlaro ) Capsule
• Laboratory Tests for Heart and Kidney Transplant Rejection
• Lenvatinib (Lenvima )
• Lusutrombopag (Mulpleta®) Tablet
• Migalastat (Galafold ) Capsule
• Mogamulizumab-kpkc (Poteligeo®)
• Molecular Testing for the Management of Pancreatic Cysts, Barrett Esophagus, and Solid Pancreatic Lesions
• Multiple Sclerosis Self Injectable Therapy
• Natalizumab (Tysabri®) IV
• Neurolysis/Ablation
• Neuropsychological Testing
• Nivolumab (Opdivo )
• Ocrelizumab (Ocrevus ) Infusion
• Patisiran (Onpattro™)
• Pembrolizumab (Keytruda®) Injection
• Preventive Services
• Ribociclib (Kisqali )
• Sipuleucel-T (Provenge )
• Teriflunomide (Aubagio®) Tablet
• Trametinib (Mekinist™) Tablets
• Transcranial Magnetic Stimulation
• Tumor/Genetic Markers
• Vandetanib (Caprelsa®) Tablets
• Vemurafenib (Zelboraf™)

Click here to view the Florida Blue Cross Blue Shield Medical Policy Updates »

Policy Alerts monitors Commercial and Medicare medical policies for changes. While medical Insurance carriers typically update medical policies annually, there are many reasons why they might review or update a policy. When reviews occur out of cycle they often go unnoticed. Policy Alerts keeps you updated when Payers make coverage changes to medical policies affecting your business.

Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on medical Insurance decisions in real-time. When changes occur, instant email alerts are delivered to your inbox. Clients have access to detailed coverage reports and medical policies through the interactive Policy Alerts Dashboard portal. Save time each month and keep focused on important Payer medical policy reviews and coverage decisions affecting your business!

Policy Alerts takes a client-focused hands-on approach and is constantly working to provide our customers with helpful insights and actionable analytics. We understand what our clients need and are dedicated to providing timely, accurate, and always up-to-date reports.

Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.